Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2011 1
2014 1
2015 1
2016 3
2017 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.
Gionfriddo I, Brunetti L, Mezzasoma F, Milano F, Cardinali V, Ranieri R, Venanzi A, Pierangeli S, Vetro C, Spinozzi G, Dorillo E, Wu HC, Berthier C, Ciurnelli R, Griffin MJ, Jennings CE, Tiacci E, Sportoletti P, Falzetti F, de Thé H, Veal GJ, Martelli MP, Falini B. Gionfriddo I, et al. Among authors: griffin mj. Leukemia. 2021 Sep;35(9):2552-2562. doi: 10.1038/s41375-021-01192-7. Epub 2021 Mar 2. Leukemia. 2021. PMID: 33654209 Free PMC article. Clinical Trial.
Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction.
Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger C, Burke O, Chan Y, Harding JE, Yockell-Lelièvre J, Hu Y, Chappell LC, Griffin MJ, Shennan AH, Magee LA, Gruslin A, von Dadelszen P. Benton SJ, et al. Among authors: griffin mj. Placenta. 2016 Jun;42:1-8. doi: 10.1016/j.placenta.2016.03.010. Epub 2016 Mar 23. Placenta. 2016. PMID: 27238707 Free article.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R. Jamieson D, et al. Among authors: griffin mj. Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28. Eur J Cancer. 2016. PMID: 27693888 Clinical Trial.
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, Makin G, Halford SE, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez A, Lyons JF, Boddy AV, Griffin MJ, Yule M, Hargrave D. Moreno L, et al. Among authors: griffin mj. Clin Cancer Res. 2015 Jan 15;21(2):267-73. doi: 10.1158/1078-0432.CCR-14-1592. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370467 Clinical Trial.